Hyperpharmacotherapy in ageing cystic fibrosis patients: The first report of an atypical hip fracture
- PMID: 26744685
- PMCID: PMC4682004
- DOI: 10.1016/j.rmcr.2015.09.013
Hyperpharmacotherapy in ageing cystic fibrosis patients: The first report of an atypical hip fracture
Abstract
Cystic fibrosis (CF) is a common autosomal recessive disorder in Caucasian populations with respiratory, gastrointestinal and endocrine manifestations. Thanks to recent advances in medical therapies and infection control, life expectancy of a patient with CF has significantly increased from less than 5 years in the mid-1900s to almost 50 years nowadays. However, as CF patients are living longer, multimorbidity and Hyperpharmacotherapy are becoming more common. This case illustrates a cascade of problems that ensued from medication side-effects, highlighting the increasing challenge of managing an ageing CF population.
Keywords: Bisphosphonate; Bone mineral density; Fracture; Multimorbidity.
References
- 
    - O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet. 2009;373(9678):1891–1904. - PubMed
 
- 
    - Dodge J.A., Lewis P.A., Stanton M., Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur. Respir. J. 2007;29(3):522–526. - PubMed
 
- 
    - UK. Annual Data Report. CF Trust Annual Report. 2012.
 
- 
    - Paccou J., Zeboulon N., Combescure C., Gossec L., Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif. Tissue Int. 2010;86(1):1–7. - PubMed
 
Publication types
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
 
         
              